Study: CSII treatment boosts glucose control in type 1 diabetes

Continuous subcutaneous insulin infusion treatment was effective in lowering A1C levels in children with type 1 diabetes, with improvements sustained at 48 months, according to a study presented at the annual meeting of the Pediatric Academic Societies. CSII treatment lacks cost-effectiveness but is safe and well-tolerated compared with multiple daily injections, researchers said.

View Full Article in:

CSII therapy improved HbA1c in children with type 1 diabetes - Endocrine Today

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Executive Officer
UCare Minnesota
Minneapolis, MN